This protocol addresses subcutaneous panniculitis-like T-cell lymphoma (SPTCL) in patients presenting with hemophagocytic lymphohistiocytosis (HLH), systemic disease, or high tumor burden — defined by widespread subcutaneous involvement.
These presentations represent a clinically demanding subset of SPTCL in which the disease has extended beyond localised cutaneous involvement and requires a more intensive management strategy.
SPTCL becomes particularly complex when accompanied by HLH — a severe inflammatory complication — or when systemic involvement or extensive subcutaneous disease (high tumor burden) is present.
For eligible patients in this setting, the approach may include enrollment in a clinical trial or, in selected cases, a specific type of cellular therapy. Alternate regimens are also considered depending on individual patient factors.
The full structured protocol — including specific regimen options, sequencing, and eligibility criteria — is available via the link below.
SPTCL with HLH, Systemic Disease, or High Tumor Burden (Widespread Subcutaneous Disease)
In cases complicated by HLH, treatment of HLH concurrently with treatment of lymphoma is recommended.
Patients with disease relapse or refractory disease after multiple prior therapies may be recommended to enroll in clinical trials or to consider allogeneic HCT (if eligible).
View source ↗